

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5667344

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	NUNC PRO TUNC ASSIGNMENT
EFFECTIVE DATE:	09/14/2016
CONVEYING PARTY DATA	
Name	Execution Date
YU-LI LIU	07/23/2018
RECEIVING PARTY DATA	
Name:	NATIONAL HEALTH RESEARCH INSTITUTES
Street Address:	35 KEYAN ROAD
Internal Address:	ZHUNAN
City:	MIAOLI COUNTY
State/Country:	TAIWAN
Postal Code:	350
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16332628
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	619-744-2200
Email:	amherrman@duanemorris.com
Correspondent Name:	DUANE MORRIS LLP - SAN DIEGO
Address Line 1:	750 B STREET
Address Line 2:	SUITE 2900
Address Line 4:	SAN DIEGO, CALIFORNIA 92101-4681
ATTORNEY DOCKET NUMBER:	G4590-01201_NHRI
NAME OF SUBMITTER:	VICKI G. NORTON
SIGNATURE:	/Vicki G. Norton/
DATE SIGNED:	08/14/2019
Total Attachments: 3	
source=PC0098_Assignment_NHRI#page1.tif	
source=PC0098_Assignment_NHRI#page2.tif	
source=PC0098_Assignment_NHRI#page3.tif	

NUNC PRO TUNC ASSIGNMENT

WHEREAS I, Yu-Li LIU having an address of 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan (R. O. C.), hereinafter referred to as "Assignor" believe I am the original, joint and first inventor of the subject matter which is claimed and for which a patent is sought on the invention(s) entitled:

Provisional Application:

Title: COMPOUNDS
Serial Number: US 62/394,479
Filing Date: 14 September 2016

PCT application

Title: NOVEL SUBSTITUTED BENZIMIDAZOLE
DERIVATIVES AS D-AMINO ACID OXIDASE (DAAO)
INHIBITORS

International
Application No.: PCT/US2017/051610
Filing Date: 14 September 2017

WHEREAS, NATIONAL HEALTH RESEARCH INSTITUTES, an entity having a place of business located at 35 KEYAN ROAD, ZHUNAN, MIAOLI COUNTY 350, TAIWAN, R.O.C., ereinafter referred to as "Assignee" is desirous of acquiring the Patent Application(s) and the invention(s) described in the Patent Applications;

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, we, the undersigned Assignors, effective as of 14 September 2016, hereby confirm that we have agreed to sell, assign, transfer, and convey and by these presents do sell, assign, transfer, and convey unto the Assignee, its successors, and assigns, my entire right, title, and interest

in and to the invention(s) described in the Patent Application for the territory of the United States and its possessions and territories and for the territory of all foreign countries worldwide;

in and to the Patent Application and all inventions and improvements that are described and/or claimed in the Patent Application, or any U.S. or foreign patent or application that claims or is entitled to claim the benefit of the priority date of said application, including any utility application ("said utility application"); any continuation, continuation-in-part, or divisional application of said utility application; any patent(s) that issue from the foregoing application(s), including any utility patents and models; any patent(s) that issue from the foregoing application(s) and are subjected to *inter partes* review, supplemental examination, reexamination, reissue, substitutes, any post-grant proceeding, or the like; and any design registrations granted for any of

the inventions or improvements described in the foregoing application(s) or patent(s); all rights in any inventions and improvements that are described and/or claimed in any patents and/or patent applications that claim or are entitled to claim priority to the filing date of any one or more of the foregoing applications and that are filed in accordance with the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purpose; together with rights of priority created by such patent applications under any international treaty or convention relating thereto, including any rights accrued by the publication of the applications, such as 35 U.S.C. § 154(d), Art. 67(1), and any rights arising from the invention under laws and conventions protecting copyright, trademark, trade dress, or other industrial property, together with all rights of priority created by such patent applications under any international treaty or convention relating thereto; and

such invention(s), application(s), and patent(s) to be held and enjoyed by the Assignee, for the Assignee's own use and benefit, and for that of the Assignee's successors and assigns, until the end of the full term or terms for which such patent(s) may be granted, as fully and entirely as the same would have been held by the Assignors had this sale, assignment, transfer, and conveyance not been made.

Assignors authorize the Assignee or the Assignee's representative to insert the application number and filing date of this application into this Assignment or any application claiming priority thereto if they are unknown at the time this Assignment is executed.

Assignors agree that, when requested, they will, without charge to the Assignee but at their own expense, sign all papers, take all rightful oaths, make all rightful declarations, and do all acts which may be necessary, desirable, or convenient for securing and maintaining patents or other forms of protection for the invention(s) in any and all countries, and for vesting title thereto in the Assignee or its successors or assigns.

Assignors agree to communicate to the assignee or its representatives any facts known to the Assignors respecting the invention(s) and, when requested by the Assignee and at its expense, will testify in any legal proceedings, and generally do everything possible to aid the Assignee, its successors, assigns, and legal representatives, to obtain and enforce protection for the invention(s) in any and all countries.

Assignors agree that a copy of this Assignment shall be deemed a full, legal, and formal equivalent of any assignment, consent to file, or like document which may be required in any country for any purpose, and more particularly, in proof of the right of the Assignee, or its successors, assigns, and legal representatives to apply for patent or other protection for the invention(s), and to claim the benefits of the right of priority provided by any relevant international treaty or convention relating to any of the aforementioned patent applications.

Assignors covenant with the Assignee, its successors, assigns, and legal representatives, that to the best of the Assignors knowledge, the right, title and interest herein conveyed by the Assignors to the Assignee are free and clear of any encumbrance and that the Assignors have the right to sell, assign, transfer, and convey the same.

Int'l App. No. PCT/US2017/051610

Date: Jul 23, 2018

By: Yu-Li LIU
Yu-Li LIU

AGREE TO BY NATIONAL HEALTH RESEARCH INSTITUTES:

Signature: ✓ Kung-Yee Liang

Name: Kung-Yee Liang

Title: President

Date: ✓ Oct. 16, 2018